Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Zhang, Xiaotian; Liang, Han; Li, Ziyu; Xue, Yingwei; Wang, Yanong; Zhou, Zhiwei; Yu, Jiren; Bu, Zhaode; Chen, Lin; Du, Ye; Wang, Xinbao; Wu, Aiwen; Li, Guoli; Su, Xiangqian; Xiao, Gang; Cui, Ming; Wu, Dan; Chen, Li; Wu, Xiaojiang; Zhou, Yanbing; Zhang, Lianhai; Dang, Chengxue; He, Yulong; Zhang, Zhongtao; Sun, Yihong; Li, Yong; Chen, Huanqiu; Bai, Yuxian; Qi, Changsong; Yu, Peiwu; Zhu, Guanbao; Suo, Jian; Jia, Baoqing; Li, Leping; Huang, Chang‐Ming; Li, Fēi; Ye, Yingjiang; Xu, Hui; Wang, Xin; Yuan, Yang; Jian‐Yu, E; Ying, Xiangji; Yao, Chen; Shen, Lin; Ji, Jiafu

doi:10.1016/s1470-2045(21)00297-7

Cited by 243 publications

(216 citation statements)

References 30 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…The study met its primary endpoint of demonstrating the superiority of neoadjuvant chemotherapy with a three-year disease-free survival of 62% for the neoadjuvant arm compared to 54.8% for the standard arm (HR 0.79, 95% CI 0.62–0.99, p = 0.045). Non-inferiority of adjuvant XELOX compared to adjuvant SOX was additionally demonstrated in this trial [ 23 , 24 ].…”

Section: Resultsmentioning

confidence: 82%

(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences

Zander

Wagner

2022

Cancers

View full text Add to dashboard Cite

Adenocarcinoma of the esophagus and gastroesophageal junction is a common disease. This disease is significantly more prevalent in men, although the main underlying risk factor has an equal sex distribution. In locally advanced disease, multimodal therapy has been developed as the standard in the western world. Neoadjuvant chemoradiotherapy or perioperative chemotherapy using the FLOT regimen was established as the standard. Most recently, adjuvant immunotherapy after neoadjuvant chemoradiotherapy and surgery has been introduced into the multimodal therapy. Substantial sex-specific differences in outcome in multimodal therapy have been described in retrospective subgroup analysis. Further studies are warranted to dissect the sex-specific differences in these treatment regimens.

show abstract

Section: Resultsmentioning

confidence: 82%

(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences

Zander

Wagner

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Advanced gastric cancer accounts for the majority in China, and radical surgical resection remains to be the most effective treatment strategy ( 3 ). The prognosis of advanced gastric cancer has improved dramatically over the recent decades due to the implement of novel surgical techniques, progression of chemotherapeutics and targeted drugs ( 4 – 6 ). However, the survival for patients with local or distant metastasis remains poor ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Integrin-β6 Serves as a Potential Prognostic Serum Biomarker for Gastric Cancer

Sun

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Discovering novel biomarkers that easily accessed is a key step towards the personalized medicine approach for gastric cancer patients. Integrin-β6 (ITGB6) is a subtype of integrin that is exclusively expressed on the surface of epithelial cells and is up-regulated in various tumors. In the present study, a retrospective cohort with 135 gastric cancer patients and a prospective cohort with 34 gastric cancer patients were constructed, ITGB6 expression were detected in both the serum specimens and the tissue specimens. Detailed clinicopathological parameters as well as patients’ survival were recorded. A nomogram including ITGB6 expression was also constructed and validated to predict the prognosis of gastric cancer patients. Results showed that serum ITGB6 expression was obviously increased and associated with tumor stage in gastric cancer patients, serum ITGB6 expression was relatively high in patients with liver metastasis. High ITGB6 expression indicated a poor prognosis, and nomogram including serum ITGB6 expression could predict the prognosis of gastric cancer patients effectively. Moreover, serum ITGB6 expression was associated with ITGB6 expression in tumor tissues. Furthermore, combined serum ITGB6 and CEA levels contributed to the risk stratification and prognostic prediction for gastric cancer patients. In addition, the serum expression of ITGB6 decreased significantly after radical surgery, and a new rise in serum ITGB6 expression indicated tumor recurrence or progression. The present study identified a novel serum biomarker for the risk stratification, prognostic prediction and surveillance of gastric cancer patients.

show abstract

“…Secondly, the population-based studies were performed in western countries, whereas the observational cohort studies were mostly performed in Asian countries. The prevalence of gastric cancer in western countries is low compared to the prevalence in Asian countries, and types of histology vary among these different parts of the world where diffuse type is more common in Asian countries [ 1 , 2 , 43 , 44 , 45 ]. The observational cohort studies revealed large heterogeneity within and across these studies.…”

Section: Discussionmentioning

confidence: 99%

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

Rijken

Lurvink

Luyer

et al. 2021

JCM

View full text Add to dashboard Cite

The peritoneum is a common metastatic site in gastric cancer. This systematic review provides an overview of the incidence, risk factors and survival of synchronous peritoneal metastases from gastric cancer. A systematic search was performed to identify studies wherein the incidence, risk factors and survival of gastric cancer with peritoneal metastases were investigated. Of all 38 potentially eligible studies, 17 studies were included based on the eligibility criteria. The incidence of synchronous gastric peritoneal metastases was reviewed for population-based studies (10–21%), for observational cohort studies (2–15%) and for surgical cohort studies (13–40%). Potential risk factors for synchronous gastric peritoneal metastases were younger age, non-cardia gastric cancer, female sex, signet ring cell carcinoma, diffuse type histology or linitis plastica, T4 stage, Hispanic ethnicity and more than one metastatic location. Synchronous peritoneal metastases are commonly diagnosed in patients with gastric cancer with an incidence up to 21% in recent population-based studies. Furthermore, prognosis of patients with gastric peritoneal metastases is poor with median overall survival ranging from 2 to 9 months. The high incidence and poor prognosis require intensive research on diagnostic features and effective treatment options to improve survival.

show abstract

Cited by 243 publications

References 30 publications

(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences

(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences

Integrin-β6 Serves as a Potential Prognostic Serum Biomarker for Gastric Cancer

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

Contact Info

Product

Resources

About